Birchview Capital’s Avalo Therapeutics AVTX Stock Holding History

Birchview Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-31,000	Closed	-$394K	–	70
2025 Q3	$394K	Buy	+31,000	New	+$267K	0.3%	52

Other funds holding AVTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Birchview Capital's AVTX Position: Q4 2025 in Review

Birchview Capital sold out of Avalo Therapeutics (AVTX) in Q4 2025, closing a stake of 31,000 shares — an estimated $394K sold.

Birchview Capital first reported a position in AVTX in Q3 2025 and held it in 1 quarter. The position peaked at $394K in Q3 2025. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

Birchview Capital reported no remaining Avalo Therapeutics position as of Q4 2025 after selling out during the quarter.
Birchview Capital sold 31,000 Avalo Therapeutics shares in Q4 2025, an estimated $394K.
Birchview Capital first reported a position in Avalo Therapeutics in Q3 2025 and held it in 1 quarter.
Birchview Capital's Avalo Therapeutics position peaked at $394K in Q3 2025.
84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.